Subtopic Deep Dive
Immune Response to Hepatitis B Virus
Research Guide
What is Immune Response to Hepatitis B Virus?
Immune response to Hepatitis B Virus encompasses the interplay of innate immunity, T-cell and B-cell adaptive responses that determine acute clearance versus chronic persistence of HBV infection.
Studies focus on T-cell exhaustion in chronic HBV and B-cell production of anti-HBs antibodies for seroconversion. Therapeutic strategies target immune restoration using checkpoint inhibitors and vaccines. Over 10,000 papers cite foundational works like Lok and McMahon (2007, 3090 citations) on chronic hepatitis B.
Why It Matters
Understanding HBV immune responses guides development of curative therapies beyond nucleos(t)ide analogs, reducing hepatocellular carcinoma risk. Terrault et al. (2018, 4077 citations) AASLD guidance highlights immune-based treatments for HBsAg loss. Liaw et al. (2004, 2263 citations) showed lamivudine delays progression in advanced chronic HBV by supporting immune control, impacting 250 million chronic carriers worldwide.
Key Research Challenges
T-cell Exhaustion in Chronic HBV
PD-1 upregulation causes HBV-specific T-cell dysfunction, hindering viral clearance. Lok and McMahon (2007) describe exhausted T-cells in chronic infection. Reversing exhaustion requires checkpoint blockade without hyperactivation.
Weak B-cell Seroconversion
Chronic HBV suppresses anti-HBs antibody production despite HBsAg presence. Terrault et al. (2018) note rare HBsAg loss in guidelines. Therapeutic vaccines aim to boost B-cell responses.
Innate Immunity Evasion
HBV subverts interferon responses for persistent infection. Sarin et al. (2015, 2504 citations) guidelines address innate defects in Asian-Pacific cohorts. Targeting cGAS-STING pathways poses safety risks.
Essential Papers
Diagnosis, Staging, and Management of Hepatocellular Carcinoma: 2018 Practice Guidance by the American Association for the Study of Liver Diseases
Jorge A. Marrero, Laura Kulik, Claude B. Sirlin et al. · 2018 · Hepatology · 4.4K citations
Marrero, Jorge A.; Kulik, Laura M.; Sirlin, Claude B.; Zhu, Andrew X.; Finn, Richard S.; Abecassis, Michael M.; Roberts, Lewis R.; Heimbach, Julie K. Author Information
Update on prevention, diagnosis, and treatment of chronic hepatitis B: AASLD 2018 hepatitis B guidance
Norah A. Terrault, Anna S. Lok, Brian J. McMahon et al. · 2018 · Hepatology · 4.1K citations
Potential conflict of interest: Dr. Hwang received grants from Merck and Gilead. Dr. Chang advises Arbutus. Dr. Lok received grants from Gilead and Bristol‐Myers Squibb. Dr. Jonas consults for Gile...
Papillomaviruses and cancer: from basic studies to clinical application
Harald zur Hausen · 2002 · Nature reviews. Cancer · 4.0K citations
Chronic hepatitis B
Anna S. Lok, Brian J. McMahon · 2007 · Hepatology · 3.1K citations
Asian-Pacific clinical practice guidelines on the management of hepatitis B: a 2015 update
Shiv Kumar Sarin, Manoj Kumar, George Lau et al. · 2015 · Hepatology International · 2.5K citations
Lamivudine for Patients with Chronic Hepatitis B and Advanced Liver Disease
Yun‐Fan Liaw, Joseph J.�Y. Sung, Wan Cheng Chow et al. · 2004 · New England Journal of Medicine · 2.3K citations
Continuous treatment with lamivudine delays clinical progression in patients with chronic hepatitis B and advanced fibrosis or cirrhosis by significantly reducing the incidence of hepatic decompens...
Asia–Pacific clinical practice guidelines on the management of hepatocellular carcinoma: a 2017 update
Masao Omata, Ann‐Lii Cheng, Norihiro Kokudo et al. · 2017 · Hepatology International · 2.1K citations
Reading Guide
Foundational Papers
Start with Lok and McMahon (2007, 3090 citations) for chronic HBV immunology overview, then Liaw et al. (2004, 2263 citations) for immune-modulating antiviral effects in advanced disease.
Recent Advances
Terrault et al. (2018, 4077 citations) AASLD update on immune-based treatments; Sarin et al. (2015, 2504 citations) Asian-Pacific guidelines on seroconversion strategies.
Core Methods
TCR sequencing for HBV-specific clones, PD-1 blockade assays, and HBsAg quantification via ELISA; vaccine trials use immunogenicity endpoints like anti-HBs titers.
How PapersFlow Helps You Research Immune Response to Hepatitis B Virus
Discover & Search
Research Agent uses searchPapers('immune response chronic HBV T-cell exhaustion') to retrieve Terrault et al. (2018), then citationGraph reveals 4000+ downstream papers on immune therapies, and findSimilarPapers expands to checkpoint inhibitor trials.
Analyze & Verify
Analysis Agent applies readPaperContent on Lok and McMahon (2007) to extract T-cell exhaustion metrics, verifyResponse with CoVe checks claims against AASLD guidelines, and runPythonAnalysis performs GRADE scoring on evidence levels for seroconversion rates using pandas for meta-analysis.
Synthesize & Write
Synthesis Agent detects gaps in B-cell vaccine efficacy via contradiction flagging across trials, while Writing Agent uses latexEditText for immune pathway revisions, latexSyncCitations integrates Liaw et al. (2004), and latexCompile generates polished review sections with exportMermaid for T-cell exhaustion diagrams.
Use Cases
"Analyze survival data from lamivudine trials in chronic HBV with advanced fibrosis"
Research Agent → searchPapers → Analysis Agent → runPythonAnalysis (pandas survival curves on Liaw et al. 2004 data) → matplotlib Kaplan-Meier plot output.
"Draft LaTeX review on HBV immune checkpoints with citations"
Synthesis Agent → gap detection → Writing Agent → latexEditText → latexSyncCitations (Terrault 2018) → latexCompile → PDF with HBV response figure.
"Find code for HBV epitope prediction models from papers"
Research Agent → exaSearch('HBV T-cell epitope prediction') → Code Discovery → paperExtractUrls → paperFindGithubRepo → githubRepoInspect → NetMHCpan implementation.
Automated Workflows
Deep Research workflow conducts systematic review of 50+ HBV immunity papers: searchPapers → citationGraph → DeepScan 7-step verification → structured report on T/B-cell dynamics. Theorizer generates hypotheses on innate evasion from Lok (2007) abstracts. DeepScan analyzes Terrault (2018) guidelines with CoVe checkpoints for therapy recommendations.
Frequently Asked Questions
What defines immune response to HBV?
It includes innate interferon responses, HBV-specific CD8 T-cells for clearance, and B-cells producing anti-HBs for resolution, failing in chronic cases per Lok and McMahon (2007).
What methods study HBV immunity?
ELISPOT assays quantify T-cell responses, flow cytometry profiles exhaustion markers like PD-1, and viral load/ALT track immune flares as in Terrault et al. (2018) guidelines.
What are key papers on HBV immune response?
Lok and McMahon (2007, 3090 citations) on chronic HBV; Terrault et al. (2018, 4077 citations) AASLD guidance; Liaw et al. (2004, 2263 citations) on lamivudine immune effects.
What open problems exist?
Restoring T-cell function without flares, achieving functional cure via vaccines, and biomarkers for immune control beyond HBsAg loss remain unsolved per Sarin et al. (2015).
Research Hepatitis B Virus Studies with AI
PapersFlow provides specialized AI tools for Medicine researchers. Here are the most relevant for this topic:
Systematic Review
AI-powered evidence synthesis with documented search strategies
AI Literature Review
Automate paper discovery and synthesis across 474M+ papers
Find Disagreement
Discover conflicting findings and counter-evidence
Paper Summarizer
Get structured summaries of any paper in seconds
See how researchers in Health & Medicine use PapersFlow
Field-specific workflows, example queries, and use cases.
Start Researching Immune Response to Hepatitis B Virus with AI
Search 474M+ papers, run AI-powered literature reviews, and write with integrated citations — all in one workspace.
See how PapersFlow works for Medicine researchers
Part of the Hepatitis B Virus Studies Research Guide